No

Abortifacient; Prostaglandin

Termination of pregnancy and refractory postpartum uterine bleeding

X

Hypersensitivity to carboprost tromethamine or any component; acute pelvic inflammatory disease; pregnancy

Use with caution in patients with history of asthma, hypotension or hypertension, cardiovascular, adrenal, renal or hepatic disease, anemia, jaundice, diabetes, epilepsy or compromised uteri

>10%: Gastrointestinal: Nausea (33%)

1% to 10%: Cardiovascular: Flushing (7%)

<1%: Hypertension, hypotension, drowsiness, vertigo, nervousness, fever, headache, dystonia, vasovagal syndrome, breast tenderness, xerostomia, vomiting, diarrhea, hematemesis, abnormal taste, bladder spasms, myalgia, blurred vision, coughing, asthma, respiratory distress, septic shock, hiccups

Increased toxicity: Oxytocic agents

Refrigerate ampuls

Carboprost tromethamine is a prostaglandin similar to prostaglandin F₂ alpha (dinoprost) except for the addition of a methyl group at the C-15 position. This substitution produces longer duration of activity than dinoprost; carboprost stimulates uterine contractility which usually results in expulsion of the products of conception and is used to induce abortion between 13-20 weeks of pregnancy. Hemostasis at the placentation site is achieved through the myometrial contractions produced by carboprost.

Adults: I.M.:

Refractory postpartum uterine bleeding: Initial: 250 mcg; may repeat at 15- to 90-minute intervals to a total dose of 2 mg

Bladder irrigation for hemorrhagic cystitis (refer to individual protocols): [0.4-1.0 mg/dL as solution] 50 mL instilled into bladder 4 times/day for 1 hour

May cause drowsiness or nervousness; rare reports of dystonia

None reported

No information available to require special precautions

No effects or complications reported

This medication is used to stimulate expulsion of uterine contents (fetal tissue) or stimulate uterine contractions to reduce uterine bleeding. Report increased blood loss, acute abdominal cramping, persistent elevation of temperature, foul-smelling vaginal discharge. Increased temperature (elevated temperature) may occur 1-16 hours after therapy and last for several hours. Pregnancy precautions: If being treated for hemorrhagic cystitis, inform prescriber if pregnant.

Do not inject I.V. (may result in bronchospasm, hypertension, vomiting and anaphylaxis)

Injection: Carboprost 250 mcg and tromethamine 83 mcg per mL (1 mL)